Advances in the Management of Metastatic Breast Cancer
نویسندگان
چکیده
Recent advances in the understanding of molecular underpinnings metastatic breast cancer have led to identification novel therapeutic targets. The latest update NCCN Guidelines for Breast Cancer reflects a rapidly evolving treatment landscape, highlighting growing importance combination therapies and personalized medicine managing estrogen-receptor (ER)–positive, HER2-positive, triple-negative subtypes. For patients with ER-positive disease, standard care remains involving cyclin-dependent kinase 4/6 inhibitors, endocrine therapy, PI3 kinase. In HER2-positive use fam-trastuzumab deruxtecan-nxki tucatinib demonstrated improved outcomes. those cancer, pembrolizumab, PARP antibody–drug conjugates (eg, sacituzumab govitecan-hziy) shown activity.
منابع مشابه
the study of aaag repeat polymorphism in promoter of errg gene and its association with the risk of breast cancer in isfahan region
چکیده: سرطان پستان دومین عامل مرگ مرتبط با سرطان در خانم ها است. از آنجا که سرطان پستان یک تومور وابسته به هورمون است، می تواند توسط وضعیت هورمون های استروئیدی شامل استروژن و پروژسترون تنظیم شود. استروژن نقش مهمی در توسعه و پیشرفت سرطان پستان ایفا می کند و تاثیر خود را روی بیان ژن های هدف از طریق گیرنده های استروژن اعمال می کند. اما گروه دیگری از گیرنده های هسته ای به نام گیرنده های مرتبط به ا...
15 صفحه اولAdvances in Chemotherapy for Metastatic Breast Cancer
Despite many advances over the past few years in the adjuvant treatment of breast cancer, a significant number of patients develop metastatic disease. Furthermore, a small yet consistent percentage of women are diagnosed with de novo metastatic disease. Once the disease has spread outside the locoregional area of the breast and draining lymph nodes, it is considered incurable, historically with...
متن کاملAdvances in the management of metastatic breast cancer: options beyond first-line chemotherapy.
This article provides an overview of recent advances in chemotherapy that may be used for the treatment of patients with locally advanced or metastatic breast cancer (MBC). Key phase ii and iii trial data for eribulin mesylate, ixabepilone, and nab-paclitaxel, published since 2006, are discussed on the basis of recency, depth, and quality.Eribulin mesylate is the first monotherapy to significan...
متن کاملClinicopathological Features of Non-metastatic Triple Negative Breast Cancer
Background: Triple negative breast cancer (TNBC) is reported to be associated with a high risk of recurrence, poor overall survival (OS), and disease-free survival (DFS) rates. This study evaluated the clincopathological features and survival of non-metastatic TNBC women in the capital of Iran compared with other areas of the world. Methods: In a retrospective study, 119 women with TNBC based ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of The National Comprehensive Cancer Network
سال: 2023
ISSN: ['1540-1405', '1540-1413']
DOI: https://doi.org/10.6004/jnccn.2023.5006